285 related articles for article (PubMed ID: 23652161)
1. Neuroprotective and behavioural assessments of an imidazolium compound (DBZIM) in a rat model of Parkinson's disease induced by 6-OHDA.
Chan HH; Kumar S; Zhuo L
Eur J Pharmacol; 2013 Sep; 715(1-3):405-13. PubMed ID: 23652161
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
3. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
4. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease.
Xue YQ; Zhao LR; Guo WP; Duan WM
Neuroscience; 2007 May; 146(3):1245-58. PubMed ID: 17363174
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
Yuan H; Sarre S; Ebinger G; Michotte Y
Brain Res; 2004 Nov; 1026(1):95-107. PubMed ID: 15476701
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson's disease in rats.
Han B; Hu J; Shen J; Gao Y; Lu Y; Wang T
Eur J Pharmacol; 2013 Aug; 714(1-3):83-8. PubMed ID: 23791614
[TBL] [Abstract][Full Text] [Related]
8. Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model.
Lazzarini M; Martin S; Mitkovski M; Vozari RR; Stühmer W; Bel ED
Glia; 2013 Jul; 61(7):1084-100. PubMed ID: 23595698
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease.
Vernon AC; Palmer S; Datla KP; Zbarsky V; Croucher MJ; Dexter DT
Eur J Neurosci; 2005 Oct; 22(7):1799-806. PubMed ID: 16197521
[TBL] [Abstract][Full Text] [Related]
10. A novel selective MAO-B inhibitor with neuroprotective and anti-Parkinsonian properties.
Chan HH; Tse MK; Kumar S; Zhuo L
Eur J Pharmacol; 2018 Jan; 818():254-262. PubMed ID: 29050969
[TBL] [Abstract][Full Text] [Related]
11. Dopamine cell morphology and glial cell hypertrophy and process branching in the nigrostriatal system after striatal 6-OHDA analyzed by specific sterological tools.
Gomide V; Bibancos T; Chadi G
Int J Neurosci; 2005 Apr; 115(4):557-82. PubMed ID: 15804725
[TBL] [Abstract][Full Text] [Related]
12. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
Yuan H; Sarre S; Ebinger G; Michotte Y
J Neurosci Methods; 2005 May; 144(1):35-45. PubMed ID: 15848237
[TBL] [Abstract][Full Text] [Related]
13. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity.
Dabbeni-Sala F; Di Santo S ; Franceschini D; Skaper SD; Giusti P
FASEB J; 2001 Jan; 15(1):164-170. PubMed ID: 11149904
[TBL] [Abstract][Full Text] [Related]
14. Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra.
Knyihár-Csillik E; Chadaide Z; Mihály A; Krisztin-Péva B; Fenyo R; Vécsei L
Acta Neuropathol; 2006 Aug; 112(2):127-37. PubMed ID: 16788821
[TBL] [Abstract][Full Text] [Related]
15. Increased tyrosine hydroxylase expression accompanied by glial changes within the non-lesioned hemisphere in the 6-hydroxydopamine model of Parkinson's disease.
Schlachetzki JC; Marxreiter F; Regensburger M; Kulinich A; Winner B; Winkler J
Restor Neurol Neurosci; 2014; 32(4):447-62. PubMed ID: 24604006
[TBL] [Abstract][Full Text] [Related]
16. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
Aponso PM; Faull RL; Connor B
Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
[TBL] [Abstract][Full Text] [Related]
17. Neurorescue effects of VEGF on a rat model of Parkinson's disease.
Yasuhara T; Shingo T; Muraoka K; Kameda M; Agari T; Wen Ji Y; Hayase H; Hamada H; Borlongan CV; Date I
Brain Res; 2005 Aug; 1053(1-2):10-8. PubMed ID: 16045899
[TBL] [Abstract][Full Text] [Related]
18. Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease.
Reglodi D; Lubics A; Tamás A; Szalontay L; Lengvári I
Behav Brain Res; 2004 May; 151(1-2):303-12. PubMed ID: 15084446
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotection by 6-(methylsulfinyl)hexyl isothiocyanate in a 6-hydroxydopamine mouse model of Parkinson׳s disease.
Morroni F; Sita G; Tarozzi A; Cantelli-Forti G; Hrelia P
Brain Res; 2014 Nov; 1589():93-104. PubMed ID: 25257035
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats.
Jin F; Wu Q; Lu YF; Gong QH; Shi JS
Eur J Pharmacol; 2008 Dec; 600(1-3):78-82. PubMed ID: 18940189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
